Which antidepressant is appropriate for a 70‑year‑old man with arthritis on meloxicam and benign prostatic hyperplasia treated with tadalafil (Cialis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antidepressant Selection in a 70-Year-Old Male on Meloxicam and Tadalafil

An SSRI such as citalopram or escitalopram is the preferred antidepressant choice, avoiding SNRIs and tricyclic antidepressants due to bleeding risk with meloxicam and potential cardiovascular/urologic interactions.

Primary Drug Interaction Concerns

Meloxicam (NSAID) Interactions

  • SSRIs increase bleeding risk when combined with NSAIDs through serotonergic effects on platelet aggregation, requiring careful monitoring for gastrointestinal bleeding, bruising, or other hemorrhagic complications.
  • SNRIs (venlafaxine, duloxetine) carry even higher bleeding risk than SSRIs when combined with NSAIDs due to dual serotonin-norepinephrine effects on platelet function.
  • Tricyclic antidepressants may be safer regarding bleeding but pose significant anticholinergic burden problematic in elderly males with BPH.

Tadalafil (PDE5 Inhibitor) Considerations

  • Tadalafil 5mg daily is an appropriate treatment for BPH/LUTS with moderate evidence supporting symptom improvement 1.
  • No significant drug interactions exist between tadalafil and SSRIs, making this combination safe from a pharmacokinetic perspective.
  • Avoid combining alpha-blockers with tadalafil as guidelines specifically recommend against this combination due to lack of additive benefit 1.

Recommended Antidepressant Algorithm

First-Line Choice: Selective SSRIs

  • Citalopram 10-20mg daily or escitalopram 5-10mg daily represent optimal choices due to:
    • Lower bleeding risk compared to SNRIs
    • Minimal anticholinergic effects (critical in elderly males with BPH on tadalafil)
    • No cardiovascular QT prolongation concerns at standard geriatric doses
    • No interference with tadalafil metabolism

Second-Line Options

  • Mirtazapine 7.5-15mg at bedtime if sedation is desired and patient has insomnia:

    • No serotonergic platelet effects (lower bleeding risk with meloxicam)
    • Minimal anticholinergic activity
    • May improve appetite if patient has weight loss

  • Bupropion SR 100-150mg daily if sexual dysfunction is a concern:

    • No serotonergic effects (no bleeding risk amplification)
    • Does not worsen erectile function (unlike SSRIs)
    • Activating properties may benefit apathetic depression

Avoid These Classes

  • SNRIs (duloxetine, venlafaxine): Highest bleeding risk when combined with NSAIDs
  • Tricyclic antidepressants: Anticholinergic effects worsen urinary retention risk in BPH patients, even those on tadalafil 1
  • MAO inhibitors: Multiple drug-drug interactions and dietary restrictions impractical in elderly

Critical Monitoring Parameters

Bleeding Risk Management

  • Assess for gastrointestinal bleeding symptoms (melena, hematemesis, unexplained anemia) within first 4-8 weeks of SSRI initiation with concurrent NSAID use.
  • Consider proton pump inhibitor co-prescription if patient has history of peptic ulcer disease or gastrointestinal bleeding.
  • Monitor for bruising, epistaxis, or prolonged bleeding from minor trauma.

BPH Symptom Monitoring

  • Ensure antidepressant does not worsen urinary symptoms: Anticholinergic antidepressants can precipitate urinary retention even in patients on tadalafil 1.
  • Tadalafil efficacy should be apparent within 1-4 weeks for LUTS improvement 2.
  • If urinary symptoms worsen on antidepressant, consider switching to non-anticholinergic alternative.

Common Pitfalls to Avoid

  • Do not assume all antidepressants are equivalent in elderly males with BPH: Anticholinergic burden from tricyclics or paroxetine can counteract tadalafil benefits 1.
  • Do not overlook NSAID-antidepressant bleeding synergy: This interaction is clinically significant and requires patient education about warning signs.
  • Do not add alpha-blockers to tadalafil regimen if urinary symptoms persist, as combination offers no advantage 1; instead consider 5-alpha reductase inhibitor if prostate is enlarged >30cc 1, 3.
  • Start antidepressants at half the standard adult dose in 70-year-old patients and titrate slowly to minimize adverse effects and drug interactions.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Guideline

Management of Moderate-to-Severe Benign Prostatic Hyperplasia (BPH)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Can a 70-year-old man taking tadalafil (PDE5 inhibitor) 5 mg for Benign Prostatic Hyperplasia (BPH) also take vardenafil (PDE5 inhibitor) 20 mg?
Is tadalafil (Cialis) safe for patients with a history of prostate bleeding or at increased risk of bleeding, particularly those with Benign Prostatic Hyperplasia (BPH)?
Why should a 70-year-old man with osteoarthritis treated with meloxicam and benign prostatic hyperplasia treated with tadalafil not be started on bupropion (Wellbutrin) before an SSRI, despite its lower gastrointestinal bleeding risk?
What are the considerations for using silodosin (alpha-blocker) with tadalafil (phosphodiesterase inhibitor) in older males with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)?
What are the side effects of Tadalafil (Cialis)?
What is the mechanism of action of cilostazol?
What are the normal reference ranges for iron studies (serum iron, ferritin, total iron‑binding capacity, transferrin saturation) and related CBC parameters (hemoglobin, mean corpuscular volume) in a healthy adult that support normal hair growth?
In an adult with type 2 diabetes and adequate renal function, is there any benefit of short‑acting (immediate‑release) metformin compared with extended‑release metformin?
What are the possible causes of an elevated ferritin level and how should it be evaluated?
How effective are cranberry tablets in preventing recurrent urinary tract infections in a post‑menopausal woman on vaginal estradiol therapy?
How should I manage a patient with type I cardiorenal syndrome (acute kidney injury secondary to acute decompensated heart failure)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question